Abstract
World Health Organization has declared in 2020 "coronavirus 2019" (COVID-2019 or 2019-nCoV or SARS-CoV-2 or CoV) as a global endemic. A recent respiratory disease produced by a novel coronavirus was born in Wuhan city of China in late December 2019. CoV is connected with a large family of viruses commonly found in cat, camel, cattle and bats. Severe acute respiratory syndrome (SARS) virus is genetically interrelated with COVID 19 strains which infect bats. MERS-CoV, SARS-CoV and SARS-CoV-2 are affected by humans from the animals. The COVID 19 is known to be the human-to-human transmission. Presently, there is no medication for COVID19, and this disease has been inherited to another global country. Pharma companies will have a major role when genomic medicine goes at the mainstream, and presently, there is no medication for COVID 19. However, genome sequencing analysis can help to design medication (Rx) by pharmacists. The genome sequencing can be identified by the next-generation sequencing (NGS) in the whole viral genome. The advantage of NGS is to identify the disease-causing or novel variants in the human genome. Limited global studies have sequenced the human genome and confirm similar to 88% of the human genome is similar to the Bats sequence in an effected person of COVID 19. This review will be connected to the pharma companies in designing the Rx for COVID 19. Thus, NGS analysis can be helpful for the pharma companies for scheming medications.